Healthcare / Medical DevicesNasdaqCM
$0.41
+0.01 (+3.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-8.3M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-283.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-16.7M · FCF $-12.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-16.7M | $-16.7M | $-11.4M | $-15.4M | $-2.0M |
| EBITDA | $-16.7M | $-16.7M | $-11.1M | $-15.3M | $-2.0M |
| EPS | — | — | -6.46 | -14.82 | -1.88 |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.13 | — |
| Current Ratio | 6.18 | 6.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.3M | $-12.3M | $-8.3M | $-6.7M | $-1.9M |
| Returns | |||||
| ROE | -283.5% | -283.5% | -140.9% | -202.2% | -309.0% |
| Valuation | |||||
| P/B | 0.80 | 0.80 | 0.36 | 7.67 | — |
| Growth & Yield | |||||
| EPS Growth | — | — | 56.4% | -686.3% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-74.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.46 → n/d
Residual
-74.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.